Geron Corporation (0IV3.L)
USD 3.93
(-1.38%)
USD 3.93
(-1.38%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 70.44 Million USD | 38.81% |
| 2022 | 139.14 Million USD | 20.59% |
| 2021 | 115.39 Million USD | 49.54% |
| 2020 | 77.16 Million USD | 5.76% |
| 2019 | 72.96 Million USD | 127.03% |
| 2018 | 32.13 Million USD | 6.0% |
| 2017 | 30.32 Million USD | -17.63% |
| 2016 | 36.8 Million USD | 3.32% |
| 2015 | 35.62 Million USD | -4.91% |
| 2014 | 37.46 Million USD | -3.39% |
| 2013 | 38.77 Million USD | -45.96% |
| 2012 | 71.76 Million USD | -22.92% |
| 2011 | 93.1 Million USD | 16.78% |
| 2010 | 79.73 Million USD | 10.8% |
| 2009 | 71.96 Million USD | 3.03% |
| 2008 | 69.84 Million USD | -0.87% |
| 2007 | 70.46 Million USD | 39.15% |
| 2006 | 50.63 Million USD | 33.26% |
| 2005 | 38 Million USD | 2.18% |
| 2004 | 37.18 Million USD | 18.61% |
| 2003 | 31.35 Million USD | -15.14% |
| 2002 | 36.94 Million USD | -4.38% |
| 2001 | 38.63 Million USD | 3.11% |
| 2000 | 37.47 Million USD | 25.33% |
| 1999 | 29.9 Million USD | 41.71% |
| 1998 | 21.1 Million USD | 6.57% |
| 1997 | 19.8 Million USD | 5.88% |
| 1996 | 18.7 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 69.76 Million USD | 24.23% |
| 2024 Q1 | 56.16 Million USD | 3.87% |
| 2023 Q3 | 47.77 Million USD | -8.09% |
| 2023 Q1 | 40.11 Million USD | -4.62% |
| 2023 Q4 | 54.07 Million USD | 13.18% |
| 2023 Q2 | 51.98 Million USD | 29.58% |
| 2023 FY | 193.14 Million USD | 38.81% |
| 2022 FY | 139.14 Million USD | 20.59% |
| 2022 Q1 | 28.79 Million USD | -10.07% |
| 2022 Q2 | 28.04 Million USD | -2.6% |
| 2022 Q3 | 40.24 Million USD | 43.48% |
| 2022 Q4 | 42.05 Million USD | 4.49% |
| 2021 Q2 | 28.99 Million USD | 1.42% |
| 2021 Q1 | 28.59 Million USD | 22.62% |
| 2021 Q3 | 25.78 Million USD | -11.08% |
| 2021 FY | 115.39 Million USD | 49.54% |
| 2021 Q4 | 32.02 Million USD | 24.2% |
| 2020 Q3 | 20.12 Million USD | 19.74% |
| 2020 Q1 | 16.92 Million USD | -43.93% |
| 2020 FY | 77.16 Million USD | 5.76% |
| 2020 Q2 | 16.8 Million USD | -0.69% |
| 2020 Q4 | 23.31 Million USD | 15.87% |
| 2019 Q3 | 16.1 Million USD | 5.08% |
| 2019 FY | 72.96 Million USD | 127.03% |
| 2019 Q1 | 11.35 Million USD | 13.99% |
| 2019 Q2 | 15.32 Million USD | 34.93% |
| 2019 Q4 | 30.17 Million USD | 87.41% |
| 2018 Q1 | 7.75 Million USD | -2.78% |
| 2018 Q2 | 7.45 Million USD | -3.93% |
| 2018 Q3 | 6.97 Million USD | -6.44% |
| 2018 Q4 | 9.96 Million USD | 42.96% |
| 2018 FY | 32.13 Million USD | 6.0% |
| 2017 FY | 30.32 Million USD | -17.63% |
| 2017 Q1 | 8.03 Million USD | -9.51% |
| 2017 Q3 | 7.4 Million USD | 7.27% |
| 2017 Q2 | 6.9 Million USD | -14.02% |
| 2017 Q4 | 7.97 Million USD | 7.7% |
| 2016 Q3 | 8.98 Million USD | -1.5% |
| 2016 Q1 | 9.82 Million USD | 10.85% |
| 2016 Q4 | 8.87 Million USD | -1.22% |
| 2016 FY | 36.8 Million USD | 3.32% |
| 2016 Q2 | 9.12 Million USD | -7.16% |
| 2015 Q1 | 9.58 Million USD | 4.33% |
| 2015 FY | 35.62 Million USD | -4.91% |
| 2015 Q3 | 8.38 Million USD | -4.61% |
| 2015 Q2 | 8.78 Million USD | -8.32% |
| 2015 Q4 | 8.86 Million USD | 5.73% |
| 2014 FY | 37.46 Million USD | -3.39% |
| 2014 Q4 | 9.18 Million USD | -8.72% |
| 2014 Q3 | 10.06 Million USD | 11.81% |
| 2014 Q1 | 9.2 Million USD | 1.49% |
| 2014 Q2 | 9 Million USD | -2.18% |
| 2013 Q2 | 8.23 Million USD | -35.38% |
| 2013 Q1 | 12.75 Million USD | -22.59% |
| 2013 FY | 38.77 Million USD | -45.96% |
| 2013 Q4 | 9.07 Million USD | 3.09% |
| 2013 Q3 | 8.79 Million USD | 6.78% |
| 2012 Q2 | 18.6 Million USD | -7.75% |
| 2012 Q3 | 16.51 Million USD | -11.26% |
| 2012 Q4 | 16.47 Million USD | -0.25% |
| 2012 FY | 71.76 Million USD | -22.92% |
| 2012 Q1 | 20.17 Million USD | -19.98% |
| 2011 Q2 | 21.87 Million USD | -15.4% |
| 2011 FY | 93.1 Million USD | 16.78% |
| 2011 Q4 | 25.21 Million USD | 25.07% |
| 2011 Q1 | 25.86 Million USD | 0.59% |
| 2011 Q3 | 20.15 Million USD | -7.87% |
| 2010 Q1 | 17.39 Million USD | -8.34% |
| 2010 FY | 79.73 Million USD | 10.8% |
| 2010 Q4 | 25.7 Million USD | 412.03% |
| 2010 Q3 | 5.02 Million USD | -71.91% |
| 2010 Q2 | 17.87 Million USD | 2.77% |
| 2009 Q4 | 18.97 Million USD | 12.33% |
| 2009 Q2 | 18.94 Million USD | 10.44% |
| 2009 Q1 | 17.14 Million USD | -26.23% |
| 2009 FY | 71.96 Million USD | 3.03% |
| 2009 Q3 | 16.89 Million USD | -10.8% |
| 2008 Q4 | 23.24 Million USD | 27.03% |
| 2008 Q2 | 15.65 Million USD | -11.26% |
| 2008 FY | 69.84 Million USD | -0.87% |
| 2008 Q3 | 18.3 Million USD | 16.89% |
| 2008 Q1 | 17.64 Million USD | -7.25% |
| 2007 Q2 | 17.65 Million USD | 1.95% |
| 2007 Q4 | 19.02 Million USD | 15.54% |
| 2007 FY | 70.46 Million USD | 39.15% |
| 2007 Q1 | 17.31 Million USD | 22.12% |
| 2007 Q3 | 16.46 Million USD | -6.74% |
| 2006 Q4 | 14.18 Million USD | 10.64% |
| 2006 FY | 50.63 Million USD | 33.26% |
| 2006 Q3 | 12.81 Million USD | 5.11% |
| 2006 Q2 | 12.19 Million USD | 6.54% |
| 2006 Q1 | 11.44 Million USD | 111.32% |
| 2005 Q2 | 8.56 Million USD | -17.79% |
| 2005 Q4 | 5.41 Million USD | -60.16% |
| 2005 FY | 38 Million USD | 2.18% |
| 2005 Q1 | 10.42 Million USD | 4.54% |
| 2005 Q3 | 13.59 Million USD | 58.66% |
| 2004 Q2 | 9.53 Million USD | 38.96% |
| 2004 Q3 | 10.57 Million USD | 10.93% |
| 2004 Q1 | 6.86 Million USD | -18.33% |
| 2004 FY | 37.18 Million USD | 18.61% |
| 2004 Q4 | 9.96 Million USD | -5.74% |
| 2003 Q3 | 5.7 Million USD | -36.13% |
| 2003 Q1 | 8.08 Million USD | 1.9% |
| 2003 Q2 | 8.93 Million USD | 10.62% |
| 2003 Q4 | 8.4 Million USD | 47.15% |
| 2003 FY | 31.35 Million USD | -15.14% |
| 2002 Q2 | 9.59 Million USD | -17.6% |
| 2002 Q3 | 7.66 Million USD | -20.2% |
| 2002 Q4 | 7.92 Million USD | 3.51% |
| 2002 Q1 | 11.64 Million USD | 30.78% |
| 2002 FY | 36.94 Million USD | -4.38% |
| 2001 Q2 | 8 Million USD | -24.66% |
| 2001 FY | 38.63 Million USD | 3.11% |
| 2001 Q4 | 8.9 Million USD | -19.75% |
| 2001 Q3 | 11.09 Million USD | 38.63% |
| 2001 Q1 | 10.62 Million USD | 9.94% |
| 2000 Q1 | 8.72 Million USD | -6.22% |
| 2000 Q4 | 9.66 Million USD | 13.81% |
| 2000 Q3 | 8.49 Million USD | -2.42% |
| 2000 FY | 37.47 Million USD | 25.33% |
| 2000 Q2 | 8.7 Million USD | -0.21% |
| 1999 Q3 | 8.6 Million USD | 38.71% |
| 1999 Q2 | 6.2 Million USD | 10.71% |
| 1999 FY | 29.9 Million USD | 41.71% |
| 1999 Q1 | 5.6 Million USD | -9.68% |
| 1999 Q4 | 9.3 Million USD | 8.14% |
| 1998 Q3 | 5.1 Million USD | 2.0% |
| 1998 Q4 | 6.2 Million USD | 21.57% |
| 1998 Q2 | 5 Million USD | 4.17% |
| 1998 Q1 | 4.8 Million USD | -5.88% |
| 1998 FY | 21.1 Million USD | 6.57% |
| 1997 Q1 | 5 Million USD | -3.85% |
| 1997 Q4 | 5.1 Million USD | 4.08% |
| 1997 FY | 19.8 Million USD | 5.88% |
| 1997 Q3 | 4.9 Million USD | 2.08% |
| 1997 Q2 | 4.8 Million USD | -4.0% |
| 1996 Q2 | 4.5 Million USD | 9.76% |
| 1996 FY | 18.7 Million USD | 0.0% |
| 1996 Q4 | 5.2 Million USD | 6.12% |
| 1996 Q3 | 4.9 Million USD | 8.89% |
| 1996 Q1 | 4.1 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Editas Medicine, Inc. | 247.3 Million USD | 71.516% |
| Dynavax Technologies Corporation | 219.14 Million USD | 67.856% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 86.684% |
| Perrigo Company plc | 1.52 Billion USD | 95.391% |
| Illumina, Inc. | 3.81 Billion USD | 98.153% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 99.313% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 84.381% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 99.827% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 96.569% |
| Heron Therapeutics, Inc. | 120.65 Million USD | 41.619% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 97.498% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -57.703% |
| Waters Corporation | 943.51 Million USD | 92.534% |
| Biogen Inc. | 5.2 Billion USD | 98.647% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 69.197% |
| Evolus, Inc. | 189.75 Million USD | 62.879% |
| Adicet Bio, Inc. | 152.03 Million USD | 53.669% |
| Cara Therapeutics, Inc. | 142.46 Million USD | 50.555% |
| bluebird bio, Inc. | 240.23 Million USD | 70.678% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 74.093% |
| FibroGen, Inc. | 398.11 Million USD | 82.306% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 96.669% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -406.419% |
| Homology Medicines, Inc. | 9.87 Million USD | -613.327% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 96.087% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 83.528% |
| Myriad Genetics, Inc. | 600.1 Million USD | 88.262% |
| Viking Therapeutics, Inc. | 100.82 Million USD | 30.137% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 87.229% |
| Zoetis Inc. | 2.76 Billion USD | 97.452% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -45.233% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 93.534% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 95.966% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 98.525% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -79.912% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 90.964% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 74.449% |
| Verastem, Inc. | 92.08 Million USD | 23.504% |
| Nektar Therapeutics | 190.9 Million USD | 63.101% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 85.213% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -480.191% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 94.824% |
| OPKO Health, Inc. | 574.68 Million USD | 87.743% |
| Exelixis, Inc. | 1.58 Billion USD | 95.561% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 95.588% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 80.89% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -26.338% |
| uniQure N.V. | 285.08 Million USD | 75.291% |
| Imunon, Inc. | 21.03 Million USD | -234.948% |
| Blueprint Medicines Corporation | 722.86 Million USD | 90.255% |
| Insmed Incorporated | 949.26 Million USD | 92.579% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 76.466% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 82.769% |
| TG Therapeutics, Inc. | 198.47 Million USD | 64.509% |
| Incyte Corporation | 1.19 Billion USD | 94.083% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 93.253% |